3 patents currently held
61 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Portola Pharmaceuticals, Inc. portfolio ends in Feb 2037, and more of its terms end in 2037 (2) than in any other year. from the record
Of the 61 now held by other companies, 46 name Alexion Pharmaceuticals Inc. as their current owner, and 15 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2037
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2037 · High confidence
Also notable
Ends Jan 2043 · High confidence
Preparation of Factor Xa Derivatives
US 11,845,966
Granted 2023. Computed term ends 2037. A terminal disclaimer caps this term to an earlier patent's.
Methods for Treating Intracranial Hemorrhage and Assessing Efficacy
US 12,685,763
Granted 2026. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Jul 2029 · High confidence
The most cited patent in this portfolio, cited by 109 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2029.
now held by Alexion Pharmaceuticals, Inc.
Also notable
Ends Jan 2034 · High confidence
Cited by 79 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2034.
now held by Alexion Pharmaceuticals, Inc.
Also notable
Ends no later than Jul 2032 · Medium confidence
Cited by 29 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 19, 2027The maintenance fee for Preparation of Factor Xa Derivatives (US 11,845,966) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 24, 2026
- Sep 20 US 11,446,300 Cerdulatinib for Treating Hematological Cancers · lapsed on the fee record
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods for Treating Intracranial Hemorrhage and Assessing Efficacy | 1 in force | to Jan 2043 |
| Preparation of Factor Xa Derivatives | 1 in force | to Jun 2037 |
| Lyophilized Formulations for Factor Xa Antidote | 1 in force | to Feb 2037 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,005,144 | Lyophilized Formulations for Factor Xa Antidote held by Alexion Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 11,845,966 | Preparation of Factor Xa Derivatives held by Alexion Pharmaceuticals, Inc. In force · High confidence | In force | High confidence | |
| US 12,685,763 | Methods for Treating Intracranial Hemorrhage and Assessing Efficacy In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 61 patents in force now held by others · 15 patents ended · 52 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
10 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed